drugset / Trial / NCT00974012

Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions

NCT00974012

Phase 1 Completed 24 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-label

Summary

This study was designed to compare the relative bioavailability (rate and extent of absorption) of Divalproex Sodium ER Tablets 500 mg with that of Depakote® ER Tablets 500 mg following a single, oral dose (1 x 500 mg extended release tablet) administered to healthy, adult subjects under non-fasting conditions.

Timeline

Start
2006-10
Primary completion
2006-10
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Divalproex Sodium Small molecule 500 mg Oral

Indications

No indication recorded.